cIAP1 Ligand-Linker Conjugates 15 are primarily used in the field of targeted cancer therapy. These conjugates are designed to specifically bind to and inhibit cIAP1, a protein involved in cell survival and apoptosis regulation. By targeting cIAP1, they promote cancer cell death while minimizing damage to healthy cells. This makes them valuable in developing precision medicines for treating various cancers, particularly those resistant to conventional therapies. Researchers also utilize these conjugates in studying apoptosis pathways and evaluating the efficacy of novel anticancer strategies. Their application extends to drug delivery systems, where they enhance the specificity and effectiveness of therapeutic agents.